Immunocore

Science to Transform Lives

Add To Watchlist
General Information
Company Name
Immunocore
Founded Year
2008
Location (Offices)
Abingdon, United Kingdom +3
Founders / Decision Makers
Bahija Jallal - Chief Executive Officer Brian Di Donato - Chief Financial Officer & Head of Strategy Ian Laing - Non Executive Director David Berman - Head of Research & Development
Number of Employees
541
Industries
Biotechnology, Health Care, Pharmaceutical
Funding Stage
Post Ipo Debt
Social Media

Immunocore - Company Profile

Immunocore is a leading T cell receptor (TCR) biotechnology company founded in 2008 and headquartered in the United Kingdom. The company's slogan "Science to Transform Lives" exemplifies its mission to create first-in-class biological therapies to address unmet patient needs in oncology, infectious, and autoimmune diseases. In its most recent funding round, Immunocore secured a significant $350.00MPost-IPO Debt investment on 30 January 2024. This further cements the company's position as a promising player in the biotechnology, health care, and pharmaceutical industries. With its ambitious goals and strong financial backing, Immunocore stands as a noteworthy contender in the biotech landscape.

Taxonomy: Pharmaceutical, Immunotherapy, T Cell Receptor, Oncology, Infectious Disease, Immune System, Biologics, Autoimmune Disease, Clinical Trials, Cancer Treatment, Biomedical Engineering, Drug Development, Biomedical Research, Immunotherapy Research

Funding Rounds & Investors of Immunocore (8)

View All
Funding Stage Amount No. Investors Investors Date
Post-IPO Debt $350.00M - 30 Jan 2024
Post-IPO Equity $140.00M 3
General Atlantic, investor in Immunocore's Post-IPO Equity round Rock Springs Capital, investor in Immunocore's Post-IPO Equity round RTW Investments, investor in Immunocore's Post-IPO Equity round
18 Jul 2022
Debt Financing $100.00M 1 Oxford Finance LLC 11 Jan 2021
Series C $75.00M 1
BlackRock, investor in Immunocore's Series C round
11 Jan 2021
Series B $130.00M 9
General Atlantic, investor in Immunocore's Series B round T1D Fund, investor in Immunocore's Series B round Bill & Melinda Gates Foundation, investor in Immunocore's Series B round CCB International, investor in Immunocore's Series B round Eli Lilly, investor in Immunocore's Series B round Rock Springs Capital, investor in Immunocore's Series B round RTW Investments, investor in Immunocore's Series B round Terra Magnum Capital Partners, investor in Immunocore's Series B round WuXi AppTec, investor in Immunocore's Series B round
02 Mar 2020

View All 8 Funding Rounds

Latest News of Immunocore

View All

No recent news or press coverage available for Immunocore.

Similar Companies to Immunocore

View All
Augmenta Bioworks, Inc. - Similar company to Immunocore
Augmenta Bioworks, Inc. Profiling individual immunity for global therapeutics
Immupeutics Medicine - Similar company to Immunocore
Immupeutics Medicine Advancing the future of tumor treatment through innovative research and application in immunotherapy.
Inventio Biyoteknoloji - Similar company to Immunocore
Inventio Biyoteknoloji Creating and manufacturing ELISA kits for diagnosing diseases.
PIN Pharma - Similar company to Immunocore
PIN Pharma A pioneering biopharmaceutical firm dedicated to creating broad-based immuno-modulatory therapies by synergizing the innate and adaptive immune systems.
The Wistar Institute - Similar company to Immunocore
The Wistar Institute The nation's first not-for-profit biomedical research organization
Circle Decoration Circle Decoration

Want to dive deeper into Immunocore? Join now to access exclusive insights and find similar companies like this — powered by AI analytics.

Register Now